Information  X 
Enter a valid email address

Mereo BioPharma Grp (MPH)

  Print   

Thursday 06 August, 2020

Mereo BioPharma Grp

Appointment of Nominated Adviser & Broker

RNS Number : 2956V
Mereo BioPharma Group plc
06 August 2020
 

Mereo BioPharma Group plc

 

("Mereo" or the "Company" or the "Group")

 

Appointment of N+1 Singer as Nominated Adviser & Broker

 

London and Redwood City, Calif., August 6, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announces the appointment of N+1 Singer as nominated adviser and broker with immediate effect.

 

For Further Information:

 

Mereo


Denise Scots-Knight, Chief Executive Officer

  +44 (0)333 023 7300

N+1 Singer (Nominated Adviser and Broker to Mereo)

   

Aubrey Powell  / Iqra Amin / Kailey Aliyar

+44 (0) 20 7496 3000



Burns McClellan (US Investor Relations Adviser to Mereo)


Lisa Burns, Steve Klass

+01 (0) 212 213 0006



FTI Consulting (UK Public Relations Adviser to Mereo)


Simon Conway, Ciara Martin

+44 (0)20 3727 1000



Investors

[email protected]



 

Notes for editors

 

About Mereo BioPharma (www.mereobiopharma.com)

 

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with oncology and rare diseases. Mereo's strategy is to selectively acquire product candidates for oncology and rare diseases that have already received significant investment from pharmaceutical and large biotechnology companies and that have substantial preclinical, clinical and manufacturing data packages.

 

Mereo's lead oncology product candidate, etigilimab, an anti-TIGIT, has completed a Phase 1a and Phase 1b for a range of solid tumor types and the second product candidate, navicixizumab, for ovarian cancer has been licensed to Oncologie Inc. for up to $300M in milestone payments. Mereo's lead rare disease product candidate, setrusumab, has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI") and a pivotal Phase 3 study design in paediatrics has been agreed with the FDA and EMA. Mereo's second lead product candidate, alvelestat, is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD"). Mereo plans to form a strategic partnership for setrusumab prior to initiation of the paediatric pivotal study.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPUVRORRBUWRUR

a d v e r t i s e m e n t